Medtronic EVP exercises 24,214 share units

Medtronic plc executive Brett A. Wall, EVP & President of Neuroscience, exercised performance-based share units that were granted on July 31, 2023.

Rhea-AI Filing Summary

Medtronic plc executive Brett A. Wall, EVP & President of Neuroscience, exercised performance-based share units that were granted on July 31, 2023. This settlement delivered 24,214 ordinary shares after performance was certified on May 26, 2026, following vesting on April 24, 2026.

After these transactions, Wall directly holds 82,183 Medtronic ordinary shares, which the disclosure notes include 527 shares acquired through dividend reinvestment since his prior report. The activity reflects compensation-related equity vesting rather than an open-market purchase or sale.

Insider Trade Summary

24,214 shares exercised/converted

Exercise 2 txns

Insider Wall Brett A.

Role EVP & Pres Neuroscience

Type	Security	Shares	Price	Value
Exercise	Performance Share Unit	24,214	$0.00	$0.00
Exercise	Ordinary Shares	26,907	$0.00	$0.00

Holdings After Transaction: Performance Share Unit — 0 contracts (Direct); Ordinary Shares — 82,183 shares (Direct)

Footnotes (4)

1. F1. Represents shares issued upon the settlement of performance-vesting share units granted on July 31, 2023, based on performance as certified on May 26, 2026.
2. F2. Includes 527 shares acquired through dividend reinvestment since the last report filed by the reporting person.
3. F3. Each performance share unit represents a contingent right to receive one share of Medtronic common stock.
4. F4. The performance share units vested on April 24, 2026.

Key Figures

Performance share units settled: 24,214 units Shares held after transaction: 82,183 shares Dividend reinvestment shares: 527 shares +3 more

6 metrics

Performance share units settled 24,214 units Each unit converted into one Medtronic ordinary share upon settlement

Shares held after transaction 82,183 shares Direct Medtronic ordinary share ownership following the reported Form 4 transactions

Dividend reinvestment shares 527 shares Shares acquired through dividend reinvestment since the last report

Transaction date May 26, 2026 Date of reported exercise/conversion transactions

Grant date of units July 31, 2023 Original grant date of the performance-vesting share units

Vesting date of units April 24, 2026 Date on which the performance share units vested

Key Terms

performance-vesting share units, dividend reinvestment, performance share unit, vested

4 terms

performance-vesting share units financial

"Represents shares issued upon the settlement of performance-vesting share units granted on July 31, 2023"

dividend reinvestment financial

"Includes 527 shares acquired through dividend reinvestment since the last report filed"

Dividend reinvestment is when the money earned from a company's profit sharing, called dividends, is automatically used to buy more shares of that company instead of being received as cash. This process helps investors grow their holdings over time without extra effort, much like using earned interest to buy more of a savings account. It encourages long-term investment growth by continuously increasing the amount of shares owned.

performance share unit financial

"Each performance share unit represents a contingent right to receive one share of Medtronic common stock"

A performance share unit (PSU) is a form of executive or employee pay that promises shares (or the cash value of shares) only if the company meets specific performance targets over a set period. Think of it like a bonus cheque that only arrives if the company hits agreed goals — it aligns managers’ rewards with business results and signals to investors how leadership is being incentivized to grow value over time.

vested financial

"The performance share units vested on April 24, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Medtronic (MDT) executive Brett A. Wall report in this Form 4?

Brett A. Wall reported exercising performance share units that were granted as equity compensation. The settlement delivered 24,214 Medtronic ordinary shares, increasing his direct holdings to 82,183 shares, including 527 acquired through dividend reinvestment since his last ownership report.

How many Medtronic (MDT) shares does Brett A. Wall own after the reported transactions?

After the transactions, Brett A. Wall directly owns 82,183 Medtronic ordinary shares. The filing notes this total includes 527 shares accumulated through dividend reinvestment since his previous filing, giving investors a clear picture of his current direct equity stake.

What equity awards were exercised by Medtronic (MDT) EVP Brett A. Wall?

Wall exercised performance-vesting share units that convert into Medtronic common stock on settlement. Each performance share unit represented a right to receive one ordinary share, and the settlement of these units delivered 24,214 shares based on certified performance results.

When did Brett A. Wall’s Medtronic (MDT) performance share units vest and settle?

The performance share units vested on April 24, 2026, and performance was certified on May 26, 2026. Following that certification, the units settled into 24,214 Medtronic ordinary shares, which are now reflected in Wall’s updated direct share ownership balance.

Are Brett A. Wall’s Medtronic (MDT) transactions open-market buys or sells?

The reported activity reflects the exercise and settlement of performance share units, not open-market trading. Wall acquired shares through equity compensation vesting, with no reported open-market purchases or sales in this Form 4, making the transactions primarily compensation-related.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/28/2026 - 04:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wall Brett A.

(Last) (First) (Middle)

710 MEDTRONIC PARKWAY

(Street)

MINNEAPOLIS MINNESOTA 55432

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medtronic plc [ MDT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Pres Neuroscience

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	05/26/2026		M		26,907(1)	A	$0	82,183(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Share Unit	(3)	05/26/2026		M			24,214	(4)	(4)	Ordinary Shares	24,214	$0	0	D

Explanation of Responses:

1. Represents shares issued upon the settlement of performance-vesting share units granted on July 31, 2023, based on performance as certified on May 26, 2026.

2. Includes 527 shares acquired through dividend reinvestment since the last report filed by the reporting person.

3. Each performance share unit represents a contingent right to receive one share of Medtronic common stock.

4. The performance share units vested on April 24, 2026.

Remarks:

	/s/ Patricia Walesiewicz, attorney-in-fact	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)